Uğur Şahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)
November 3, 2023 01:18 PM EDT
Deals

Ex­clu­sive: BioN­Tech ac­quires lipid nanopar­ti­cle start­up found­ed by George Ma­son and UPenn sci­en­tists

Ryan Cross

Senior Science Correspondent

BioN­Tech, the Ger­man drug com­pa­ny fa­mous for de­vel­op­ing a Covid-19 vac­cine with Pfiz­er, has ac­quired Aex­eR­NA and its nov­el lipid nanopar­ti­cles for mR­NA med­i­cines, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times